BPC-157 is a synthetic 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a protein fragment in human gastric juice. In preclinical models it is investigated for VEGFR2 angiogenic signalling and nitric oxide pathway modulation. Evidence comes mainly from one research group, so findings remain limited and unreplicated across independent centres.

What Is BPC-157?

BPC-157 (Body Protection Compound-157), also designated Bepecin and PL 14736, is a stable gastric pentadecapeptide first characterised in the laboratory of Professor Predrag Sikiric at the University of Zagreb, Croatia. Its 15-residue chain — Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val — was isolated from a partial sequence of a protective gastric-juice protein during systematic screening of gastric proteins for cytoprotective properties. A defining structural feature is the triple proline cluster (Pro-Pro-Pro at positions 3–5), which you can picture as a rigid, kinked segment that shields the backbone from gastric proteases and gives the molecule its characteristic stability in acidic conditions.

In laboratory settings, BPC-157 is studied across rodent models and isolated cell systems for how it interacts with tissue-repair signalling, angiogenesis, gastrointestinal mucosal cytoprotection, and growth-factor receptor expression. Researchers frequently search for terms such as "how does BPC-157 work," "BPC-157 mechanism of action," "BPC-157 half-life," and "BPC-157 VEGFR2" — all of which map to preclinical observations rather than clinical outcomes. A 2025 systematic review noted that over 80% of published BPC-157 records originate from a single research group, which limits independent multi-centre replication and should factor into how the evidence base is weighed.

Disclaimer: BPC-157 is a research compound not approved by the U.S. Food and Drug Administration (FDA) for human or veterinary use. It is not intended to diagnose, treat, cure, or prevent any disease. This product is strictly for laboratory research purposes only.

Chemical Properties of BPC-157

The following identifiers characterise research-grade BPC-157 for laboratory reference.

How Does BPC-157 Work?

In preclinical models, BPC-157 is associated with several intersecting signalling pathways, with VEGFR2 activation and nitric oxide modulation reported most often. All findings originate predominantly from one research group, and independent replication is limited.

VEGF/VEGFR2 Signalling Pathway

In rodent wound preparations and isolated endothelial cultures, BPC-157 has been associated with up-regulation of vascular endothelial growth factor receptor 2 (VEGFR2). Mechanistically, the peptide is reported to promote VEGFR2 internalisation at the endothelial cell surface and to activate the downstream VEGFR2–Akt–eNOS cascade — a sequence you can picture as receptor clustering, endocytic uptake, and phosphorylation relayed inward to endothelial nitric oxide synthase. This VEGFR2-linked signalling is proposed as a basis for the increased vessel density observed in preclinical angiogenesis assays Hsieh et al., 2016 — see reference 1.

Nitric Oxide Synthase Pathway Modulation

BPC-157 has been investigated for bidirectional modulation of the nitric oxide (NO) pathway in rodent preparations. It is reported to attenuate NO overproduction under inflammatory conditions while preserving NO availability in ischaemic tissue preparations — a dual profile attributed to context-dependent NOS isoform interaction. Both L-NAME-reversal and NOS-activation responses have been described, depending on the experimental model.

Growth Hormone Receptor (GHR) Pathway

In isolated tendon fibroblast preparations, BPC-157 exposure has been reported to increase growth hormone receptor (GHR) mRNA and protein expression, with subsequent Janus kinase 2 (JAK2) signalling activation. This GHR up-regulation is proposed as a complementary route alongside VEGFR2 signalling in preclinical tissue-repair models Chang et al., 2014 — see reference 2.

FAK-Paxillin Signalling and Cell Migration

In fibroblast cultures, BPC-157 has been associated with phosphorylation of focal adhesion kinase (FAK) and paxillin — components of the focal adhesion complex that organise the cytoskeleton and drive directional cell migration. This is proposed as a mechanism for fibroblast movement into wound beds observed in model systems.

What Are the Key Research Findings for BPC-157?

Reported observations are preclinical and predominantly from one research group; independent replication is limited.

• VEGFR2 and Akt-eNOS activation: Increased VEGFR2 expression and internalisation with Akt-eNOS activation in endothelial cells and rodent hind-limb ischaemia models Hsieh et al., 2016.

• GHR up-regulation: Dose- and time-dependent GHR mRNA/protein increase with JAK2 activation in isolated tendon fibroblasts Chang et al., 2014.

• Gastrointestinal mucosal cytoprotection: Protection against NSAID-induced and alcohol-induced gastric lesions in rodent in vivo preparations at 10–100 μg/kg.

• Tissue-repair kinetics: Accelerated repair in rodent skin-wound, muscle, tendon, and ligament models at doses as low as 10 μg/kg in published studies.

• Research-concentration caveat (2025): Over 80% of BPC-157 literature attributed to a single research group; multi-centre replication remains limited.

All findings above are derived from preclinical in vitro and in vivo data. No regulatory-grade human clinical trial data have been established, and these observations do not constitute evidence of efficacy or safety in any organism.

What Are the Research Applications of BPC-157?

In controlled laboratory environments, BPC-157 is investigated as a research tool in the following areas. These do not constitute claims of efficacy or safety.

• Angiogenesis and VEGFR2 pharmacology: Within angiogenic-peptide research, BPC-157 is used in endothelial tube-formation assays, chick chorioallantoic membrane (CAM) assays, and rodent neovascularisation models to characterise VEGFR2 signalling.

• Nitric oxide pathway research: In the context of vascular and inflammatory biology, it serves as a probe for bidirectional NOS interaction under inflammatory and ischaemic conditions.

• Gastrointestinal mucosal biology: Within cytoprotection research, it is applied in NSAID-induced ulcer models and ethanol-induced gastric injury preparations.

• Musculoskeletal repair models: In tendon, ligament, and muscle-injury research, it is examined for collagen-synthesis markers and vascular density at injury sites.

• Comparative angiogenic peptide studies: Alongside reference compounds such as GHK-Cu and TB-500, it is used to contrast angiogenic pathway activation profiles in matched experimental systems.

What Are the Risks and Limitations of BPC-157 Research?

This section is mandatory reading before working with BPC-157 in any laboratory setting.

Handling Precautions: BPC-157 should be handled by trained laboratory personnel only, in a controlled research environment. Use appropriate PPE at all times — nitrile gloves, a laboratory coat, and eye protection at minimum. Handle lyophilised powder in a laminar flow cabinet, avoid aerosol generation during reconstitution, and avoid direct skin contact or inhalation of any reconstituted solution.

Exposure Risks: BPC-157 is a synthetic pentadecapeptide research compound thought to interact with VEGFR2, nitric oxide synthase, and growth hormone receptor pathways in preclinical models. Because these targets are expressed in many tissues, accidental systemic exposure may produce pharmacological effects. No human safety data exist for this compound, and independent multi-centre safety characterisation is absent.

Storage: Store lyophilised BPC-157 at −20°C in a dry, dark environment, protected from light, heat, and moisture. Store reconstituted material at 4°C, use within 48–72 hours, and avoid repeated freeze-thaw cycles.

Toxicity and Data Limitations: No chronic toxicity data exist for BPC-157. Reported low-toxicity observations derive from short-duration rodent studies within a single research programme, and evidence remains limited and unreplicated across independent laboratories.

What to Look for in a Supplier When Buying Research-Grade BPC-157?

Check that every batch is independently third-party tested for purity and identity, and that a Certificate of Analysis (COA) is available for each lot. You can explore trusted sources such as RCD Bio, where all compounds are supplied strictly for preclinical and in vitro research use.

Note: All RCD Bio products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not to be used for any human or veterinary purposes.

Disclosure: Sponsored by RCD Bio. This content is for informational purposes only and does not constitute an endorsement of any product for human use.

Frequently Asked Questions

Q: What is BPC-157 investigated for in research? BPC-157 is a synthetic pentadecapeptide (GEPPPGKPADDAGLV) studied in preclinical models for VEGFR2 angiogenic signalling, nitric oxide pathway modulation, growth hormone receptor expression, and gastrointestinal mucosal cytoprotection. Most published research originates from one group. It is not FDA-approved and is intended strictly for laboratory research.

Q: How does BPC-157 work at the molecular level? In preclinical models, BPC-157 is associated with VEGFR2 internalisation and Akt-eNOS activation in endothelial cells, plus growth hormone receptor up-regulation in fibroblasts. These mechanisms are proposed, not confirmed in humans, and evidence remains limited to animal and cell-culture systems.

Q: What is the half-life of BPC-157 in preclinical models? The elimination half-life in rat IV and IM administration is roughly 7.9–30 minutes based on preclinical pharmacokinetic data. Its triple Pro-Pro-Pro sequence provides some protease resistance, consistent with its origin as a gastric-juice protein fragment. Human pharmacokinetic data are not established.

Q: Why is the concentrated BPC-157 literature a concern? A 2025 systematic review found over 80% of BPC-157 records come from one research group. This reflects sustained work but limits independent multi-centre replication, which weakens the overall strength of evidence compared with compounds studied across many programmes. Researchers should account for this when interpreting findings.

Q: How does BPC-157 compare with other angiogenic research peptides? Within angiogenic-peptide research, BPC-157 is often compared with GHK-Cu and TB-500 in matched experimental systems. Each is associated with distinct pathway-activation profiles. Comparative data remain preclinical, and no cross-compound conclusions about efficacy or safety in any organism can be drawn.

Q: Is BPC-157 FDA-approved? No. BPC-157 has been evaluated in human clinical trials for inflammatory bowel disease indications but has not received FDA approval for any indication. It is prohibited under WADA S0. Research-grade BPC-157 from RCD Bio is intended strictly for laboratory research purposes.

Final Thoughts

BPC-157 Peptide is a synthetic gastric pentadecapeptide studied in preclinical models as a research tool for VEGFR2 angiogenic signalling, nitric oxide pathway modulation, and growth hormone receptor expression. The reported mechanisms are internally coherent, but the evidence base is concentrated in one research group and remains limited, unreplicated across independent centres, and confined to rodent and cell-culture systems. No human safety or efficacy data have been established, and BPC-157 is not approved by the FDA for human or veterinary use. Researchers should treat all reported observations as preliminary and design protocols accordingly.

References

1. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2016;95(3):323–333. https://pubmed.ncbi.nlm.nih.gov/27847966/

2. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066–19077. https://pubmed.ncbi.nlm.nih.gov/25415472/

ATTENTION: This product is intended for LABORATORY AND RESEARCH PURPOSES ONLY. It is NOT for human or veterinary use, and NOT for human or animal consumption. Not a drug, food, or dietary supplement.